HB820: Health Insurance - Pediatric Autoimmune Neuropsychiatric Disorders - Modification of Coverage Requirements

Legislative Summary

Removing a requirement that rituximab be approved by the federal Food and Drug Administration to be subject to a requirement on certain insurers, nonprofit health service plans, and health maintenance organizations to provide coverage for the treatment of certain pediatric autoimmune neuropsychiatric disorders; etc.